IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Dexiang CHEN et al.

Title: INDUCTION OF MUCOSAL IMMUNITY BY VACCINATION VIA THE

SKIN ROUTE

Prior Appl. 09

09/710,104

No.:

Prior Appl.

11/09/2000

Filing Date:

Examiner: Unassigned

Art Unit: Unassigned

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56

Mail Stop PATENT APPLICATION Commissioner for Patents PO Box 1450 Alexandria, Virginia 22313-1450

Sir:

Applicant submits herewith on Form PTO/SB/08 a listing of the documents cited by or submitted to the U.S. PTO in parent application Serial No. 09/710,104, filed 11/09/2000. As provided in 37 CFR §1.98(d), copies of the documents are not being provided since they were previously submitted to the United States Patent & Trademark Office in the above-identified parent application.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the filing date of the application.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

FOLEY & LARDNER

Date

Customer Number: 27476

Telephone: Facsimile:

(202) 672-5483 (202) 672-5399

Richard C. Peet

Attorney for Applicant

Registration No. 35,792

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

number.

	Substitute for form 1449B/PTO			•	Complete if Known		
	INFORMATION D	ISCLO	SURE	Application Number	APPL_NO		
	STATEMENT BY	APPLI	CANT	Filing Date	12/02/2003		
	Date Submitted: Dec	aambar	2 2002	First Named Inventor	Dexiang CHEN		
	Date Submitted. Det	cember	2, 2003	Group Art Unit	Unassigned .		
	(use as many sheets	s as ne	cessary)	Examiner Name	Unassigned		
Sheet	1	of	4	Attorney Docket Number	036481-0143	_	

	U.S. PATENT DOCUMENTS									
Examiner Initials*	Cite No.1	U.S. Patent D	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				
	A1	4,945,050		Sanford et al.	07/31/1990					
	A2	5,100,792		Sanford et al.	03/31/1992					
	A3	5,120,657		McCabe et al.	06/09/1992					
	A4	5,149,655		McCabe et al.	09/22/1992					
	A5	5,204,253		Sanford et al.	04/0/1993					
	A6	5,346,481		Bunin	09/13/1994					
	Α7	5,503,632		Haak	04/02/1996					
	A8	5,569,468		Modi	01/29/1996					
	A9	5,584,807		McCabe	12/17/1996					
	A10	5,589,466		Felgner et al.	12/31/1996					
	A11	5,630,796		Bellhouse et al.	05/20/1997					
	A12	5,718,913		Dhuique-Mayer et al.	02/17/1998					
	A13	5,738,852		Robinson et al.	04/14/1998					
	A14	5,780,448		Davis	07/14/1998					
	A15	5,785,688		Joshi et al.	07/28/1998					
	A16	5,840,336		Hsu et al.	11/24/1998					
	A17	5,865,796		McCabe	02/02/1999					
	A18	5,871,460		Phipps et al.	02/16/1999					
	A19	5,871,751		Christensen et al.	02/16/1999					
	A20	5,900,238		Gombotz et al.	05/04/1999					
	A21	5,919,463		Thomas, Jr. et al.	04/06/1999					
	A22_	5,968,006		Hofmann	10/19/1999					
-	A23	5,983,130		Phipps et al.	11/09/1999					
	A24	5,989,586		Hsu et al.	11/23/1999					
	A25	6,008,200		Krieg	12/18/1999					
	A26	6,009,345		Hofmann	12/28/1999					
	A27	6,010,705		Thune et al.	01/04/2000					
	A28	6,049,733		Phipps et al.	04/11/2000					
	A29	6,168,587		Bellhouse et al.	01/02/2001					
	A30	6,194,389		Johnston et al.	02/27/2001					

			FOREIGN PATENT DOCUMEN	TC	.	
Examiner Initials*	Cite No.1	Foreign Patent Document Office ³ Number ⁴ Kind Code (if known)	Name of Patentee or	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Te
	A31	WO 94/24263		10/27/1994		
	A32	WO 96/02555		02/01/1996		
	A33	WO 96/04947		02/22/1996		
	A34	WO 96/12513		05/02/1996		
	A35	WO 96/14855		05/23/1996		
	A36	WO 96/20022		07/04/1996		

Examiner	Date	
Signature	Considered	
	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

	Substitute fo	or form 1449B/	/PTO	Complete if Known		
	INFORMATI	ON DISCLO	SURE	Application Number	APPL_NO	
	STATEMEN	T BY APPLI	CANT	Filing Date	12/02/2003	
	Data Cubmitta	d. Dagamban	. 2 2002	First Named Inventor	Dexiang CHEN	·
	Date Submitte	u. December	2, 2003	Group Art Unit	Unassigned	
	(use as many s	sheets as ne	cessary)	Examiner Name	Unassigned	
Sheet	2	of	4	Attorney Docket Number	036481-0143	

	FOREIGN PATENT DOCUMENTS										
Examiner Initials*	Cite No.1	Foreign Patent Document Office ³ Number ⁴ Kind Code ⁶ (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆					
	A37	WO 97/44446		11/27/1997							
	A38	WO 97/48485		12/24/1997		T					
	A39	WO 98/10750		03/19/1998							
	A40	WO 98/20734		05/22/1998		1					
	A41	WO 99/27961		06/10/1999							
	A42	WO 99/33488		07/08/1999		1					

		NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue numbe publisher, city and/or country where published.						
	A43	LOBB, C.J., (1987) Developmental and Comparative Immunology 11: 727-738 (abstract only)					
	A44	HART et al., (1988) Developmental and Comparative Immunology 12:453-480 (abstract only)					
	A45	DICKERSON et al., (1988) Immunological Reviews 166:377-384 (abstract only)					
	A46	ORKIN et al., (1995) "Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy"					
	A47	PAUL et al., (1995) Eur. J. Immunology <u>25</u> :3521-3524					
	A48	KRIEG et al., (1995) Nature <u>374</u> :546-549					
	A49	SATO et al. (1996) Science <u>273</u> :352-354					
	A50	WOOLDRIDGE et al. (1997) Blood <u>89</u> ;2994-2998					
	A51	KLINMAN, D.M. (1998) Antisense and Nucleic Acid Drug Development 8:181-184					
	A52	KRIEG, A. (1998) Biodrugs <u>10</u> :341-346					

	1	 	
Examiner Signature	Date Considered		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

	Substitute for form 1449B/PTO				Complete if Known		
	INFORMATION	DISCLO	SURE	Application Number	APPL_NO		
	STATEMENT I	BY APPLI	CANT	Filing Date	12/02/2003		
	Date Submitted: I	Dooomhor	2 2002	First Named Inventor	Dexiang CHEN		
	Date Submitted. I	December	2, 2003	Group Art Unit	Unassigned		
	(use as many she	ets as ne	cessary)	Examiner Name	Unassigned	•	
Sheet 3 of 4				Attorney Docket Number	036481-0143		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A53	MACFARLANE et al. (1998) J. Immunology <u>160</u> :1122-1131	
	A54	GLENN et al. (1998) J. Immunology <u>161</u> :3211-3214 (abstract only)	
	A55	GUY et al. (1998) Vaccine <u>16</u> :850-856 (abstract only)	
	A56	MCCLUSKIE et al. (1998) J. Immunology <u>161</u> :4463-4466	
	A57	SPARWASSER et al. (1998) J. Immunology <u>28</u> : 2045-2054	
<u> </u>	A58	PORTER et al. (1998) Archives of Virology 143:997-1003	
	A59	MOLDOVEANU et al. (1998) Vaccine <u>16</u> :1216-1224	
	A60	PAUL et al. (1998) Vaccine <u>16</u> :188-195	
	A61	SPIEGLBERG et al. (1998) Allergy <u>53</u> :93-97	

		 	_
Examiner Signature	Date Considered		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

	Substitute for form 1449B/PTO			Complete if Known		
	INFORMATION	DISCLO	SURE	Application Number	APPL_NO	
	STATEMENT B	Y APPLI	CANT	Filing Date	12/02/2003	
	Data Cubacittadi D		2 2002	First Named Inventor	Dexiang CHEN	
	Date Submitted: D	ecember	2, 2003	Group Art Unit	Unassigned	
	(use as many shee	ets as ne	cessary)	Examiner Name	Unassigned	
Sheet 4 of 4			4	Attorney Docket Number	036481-0143	

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹					
	A62	WEINER et al. (1998) Proceedings of the American Association of Cancer Research <u>39</u> :551, col. 1, abstract number 3747				
	A63	VINNER et al. (1999) Vaccine <u>17</u> :2166-2175				
	A64	MCCLUSKIE et al. (1999) Critical Reviews in Immunology 19:303-329				
	A65	SCHARTON-KERSTEN et al. (1999) Vaccine 17(suppl. 2):S37-S43				
	A66	MCCLUSKIE et al. (1999) Vaccine <u>18</u> :231-237				
	A67	GLENN (1999) Infection and Immunity <u>67</u> :1100-1106				
	A68	GLENN et al. (1999) "Avances in vaccine delivery: transcutaneous immunization," Expert Opinion On Investigational Drugs 8(6):797-805				
	A69	BABIUK et al. (2000) J. Controlled Release 66:199-214				

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.